CN1015456B - Process for preparation of 3,5-diamino-1,2,4-triazole derivatives - Google Patents
Process for preparation of 3,5-diamino-1,2,4-triazole derivativesInfo
- Publication number
- CN1015456B CN1015456B CN86100724A CN86100724A CN1015456B CN 1015456 B CN1015456 B CN 1015456B CN 86100724 A CN86100724 A CN 86100724A CN 86100724 A CN86100724 A CN 86100724A CN 1015456 B CN1015456 B CN 1015456B
- Authority
- CN
- China
- Prior art keywords
- general formula
- compound
- defined above
- triazole
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Abstract
The present invention relates to process for the preparation of 3, 5-diamino-1,2,4-triazole derivatives of formula I and the preparation of the pharmaceutically acceptable acid addition salt. The groups of the formula I are defined in the description.
Description
The present invention relates to a kind of new, improved 3,5-diaminostilbene, 2, the preparation method of 4-triazole derivative.
The invention provides 3 of formula I, the 5-diaminostilbene, 2, the preparation method of 4-triazole derivative and pharmaceutically-acceptable acid addition thereof,
Wherein
R
1And R
2Each represents hydrogen, alkyl, alkenyl, aralkyl or cycloalkyl; Or R
1And R
2Be connected with adjacent nitrogen-atoms together and generate heterocycle; R
3Represent hydrogen or alkyl.
The compound of formula I is known histamine H with persistency effects
2-encapsulant.These compounds can be treated the gastric acid secretion that causes owing to histamine, and can be used for ulcer treatment.
The known compound that has several methods to can be used to prepare formula I, according to belgian patent № 875846, the amine of general formula V
(R wherein
1And R
2As defined above) the cyanogen imine derivative with the general formula VI reacts
(R wherein
4And R
5Be alkylthio or alkoxyl group).With the isourea or the isothiourea derivatives of the general formula VII that obtains, (R wherein
1And R
2Handle as defined above) with the replacement hydrazine of general formula VIII
(R wherein
3As defined above, Z represents 2 hydrogen atoms).In this reaction, obtain the mixture (R wherein of formula I and IX isometry compound
1, R
2And R
3As defined above).By
Crystallization can be isolated the compound of formula I from this mixture.The weak point that this method is serious is, at R
3Replace the formula I that differs from one another of position and the isomer of IX and only just generate in the synthetic final step, then loss is very big to obtain the isomer of formula I.Because this loss occurs at this synthetic final step of being made up of several steps, so that make this method cost costliness.
The resultant of the general formula IX isomeric compound that generates in order to remove, according to the method that belgian patent № 875846 is introduced, the protected hydrazine derivative reaction of the isothiourea of general formula VII and general formula VIII (R wherein
3As mentioned above, Z represents a protecting group).From the protection of resulting general formula X cyanoguandine derivatives remove protecting group (R wherein
1, R
2, R
3With Z as mentioned above),
The cyanoguandine derivatives of general formula XI automatically is cyclized into the compound (R wherein of formula I
1, R
2And R
3As defined above).
According to this belgian patent, the protected hydrazine derivative of general formula VIII and the cyanogen imine derivative of general formula VI can be reacted the key intermediate species for preparing the general formula X.The protected cyanoguandine derivatives of general formula XII (R wherein
3And R
4As
The last definition, Z represents protecting group) be connected the required intermediate product that generates the general formula X with the amine of general formula V.
The common drawback of above-mentioned two kinds of methods is to need to use the protecting group Z that is used to remove general formula IX isomery triazole derivative in the closed loop procedure of triazole ring.The isomer this point that the reaction that is similar to dimethyl-N-cyanogen imido grpup-two thiocarbamate ester and N-methyl-hydrazine can cause generating the compound of formula I and IX type is known.(seeing organic chemistry magazine 39,1522,1974)] (J.org.Chem39,1522/1974).
Disclosed according to belgian patent № 875846, the isothiourea of the general formula VIII microorganism (R wherein that spreads out
1And R
2As defined above, R
8Be C
1-10Alkyl)
Can be further (wherein Y is-NH-, oxygen or sulphur, R with the thiosemicarbazide of aminoguanidine, Urea,amino-or general formula X IV
3Handle as defined above).
The compound of resulting general formula X V can be converted to the triazole derivative of formula I then by ring-closure reaction
(R wherein
1, R
2, R
3With Y as defined above, Q representative-NH-).
The further reaction process disclosed according to this belgian patent, the isocyanic ester of general formula X VI (R wherein
1And R
2As defined above, P is oxygen or sulphur)
With the compound of general formula X IV (R wherein
3As defined above, Y representative-NH-) carry out addition reaction obtains the compound of general formula X V, obtains the triazole derivative of required formula I through crystallization.
The common weak point of above-mentioned two kinds of methods is the preparation complexity of agents useful for same, and the last condensation step time is long, and consumed energy, productive rate are not high.
The reaction process that this belgian patent further discloses is the isothiourea and the protected hydrazine reaction of general formula VIII of general formula X III, to remove protecting group.The aminoguanidine derivatives of general formula X VII (R wherein
1, R
2And R
3As defined above)
Generate required generalformula with the urea chloride reaction.The shortcoming of this method is, for the isomer of the unwanted general formula IX of removing generation need use the protected hydrazine derivative (wherein Z is a protecting group) of general formula VIII, and the preparation complexity of agents useful for same, in the synthesis step sealing condensation time long, consumes energy.
The belgian patent № 875846 disclosed another kind of reactions that are different from above-mentioned reaction are to use the acid amides of general formula X VIII
(R wherein
1And R
2As defined above) or the acetal of general formula X IX or ring acetal (R wherein
6Represent alkyl or (R
6O)
2Group representative ring acetal.
The aminocompound that replaces the general formula V.This synthetic final step is to obtain the general formula R that generated from the intermediate product of the X XI of general formula XX
1, R
2, N-CH
2-group,
(R wherein
1, R
2, R
3And R
6As defined above).Method therefor is the currently known methods of synthetic general formula V compound.
Disclosed according to belgian patent № 875846, another kind of method is with a kind of key intermediate species of general formula X XII (R wherein
3As defined above, X represents halogen)
With general formula R
1, R
2NH(is R wherein
1, R
2Amine condensation as defined above).
According to european patent application № 29303, can be under reduced pressure, with the aldehyde (wherein R is as defined above) and the general formula R of general formula XX III
1, R
2The amine of NH (R wherein
1And R
2As defined above) carry out the compound that amination reaction prepares formula I.
Disclosed according to this european patent application, its further reaction be secondary amine (R wherein with general formula XX IV
1And R
3As defined above)
Be raw material and general formula R
7The aldehyde of CHO carries out reduction condensation (wherein by reduction R
7-CHO-group generates R
7-CH
2-group is the R group) or with general formula be R
7-CH
2The compound of-X (R wherein
7-CH
2-as defined above, X represents halogen) and carry out alkylated reaction, all can generate required generalformula.
In in the end described four reaction types, its reactions steps is identical with former disclosed reaction method, and just the precedence of reactions steps changes to some extent.Therefore these four methods have the identical weak point of discussing with the front of method.
The method disclosed, a group of generalformula according to belgian patent № 875846 can be by general formula XX V benzene oxyalkyl derivative (R wherein
3As defined above) with molecular formula be the ammonium chloride reaction of XX VI
And make.The R of resulting generalformula
1And R
2Be methyl.
The weak point of this method is, to carry out prepared classes of compounds limited although its preparation is suitable for.The reaction complexity for preparing the compound of general formula XX VI in addition, the cost height.
The another kind of method disclosed according to belgian patent № 875846, the aminoguanidine of general formula X IV (R wherein
3As defined above, Y represents imido grpup) with the urea chloride of general formula XX VII (R wherein
8And R
9Be suitable protecting group) reaction
Can obtain 3 of general formula XX VIII, 5-diaminostilbene H-1,2,4-triazole derivative
(R wherein
3, R
8And R
9As defined above), with the aldehyde reaction of gained compound and general formula XX IX (R wherein
1And R
2As defined above)
Obtain the Schiff's base (R wherein of general formula XXX
1, R
2, R
3, R
8And R
9As defined above),
With its reduction, slough protecting group at last.
A kind of improvement of aforesaid method is with the reaction of the active acid derivant of the aminotriazole of general formula XX VIII and general formula XX XI (wherein,
A represents halogen, hydroxyl, alkoxyl group or acyloxy) obtain the acid amides (R wherein of general formula XX XII
1, R
2, R
3, R
8And R
9As defined above), its reduction is obtained the compound of required formula I.
Aforesaid method is further improved, be about to active ester reaction (wherein R and R as defined above, B is first sulphur acyloxy or adds Toxyloxy) the required generalformula of generation of aminotriazole with the general formula XXX III of general formula XX VIII.
The shortcoming of aforesaid method is that the complicated approach of discussing with the front generates triazole ring, needs appropriate selection and removes protecting group R
6And R
9, this can cause other problem, and very inconvenient.
Target of the present invention is the shortcoming that overcomes above-mentioned known procedure, and a kind of economy is provided, the method for preparing generalformula of simple possible.
In the method for the compound of preparation formula I provided by the present invention and pharmaceutically-acceptable acid addition thereof, R
1And R
2Each represents hydrogen, alkyl, alkenyl, aralkyl or cycloalkyl; Or R
1And R
2Be connected with adjacent nitrogen-atoms together and generate heterocycle; R
3Represent hydrogen or alkyl;
This method comprises:
A) with the oxy-compound of general formula II (R wherein
3As defined above) change into the halogenated compound of general formula III, (R wherein
3
As defined above, X represents halogen), with the basic metal of resulting compound and general formula IV phenol derivatives or the salt of alkaline-earth metal (R wherein
1And R
2Reaction as defined above), or
(b) with the basic metal or the alkaline-earth metal reactant salt of the phenol derivatives of the halogenated compound of general formula III and general formula IV, the compound of resulting formula I can be converted into its pharmaceutically-acceptable acid addition if desired.
Can use known method the oxy-compound of general formula II to be converted into the halo derivatives of general formula III.
The embodiment of preferentially selecting for use is with the compound of general formula II and the halogenating agent, particularly thionyl halide that suits, preferably thionyl chloride reaction in inert solvent.The thionyl halide of preferentially selecting excess for use is as reaction medium.Aromatic hydrocarbon, for example benzene, toluene, dimethylbenzene also can be used as reaction medium.Reaction can be carried out for example 20-80 ℃ under room temperature or heating.
Then the halo derivatives of general formula III and an alkali metal salt (as calcium, magnesium) of general formula IV oxybenzene compound are reacted.Reaction can be carried out in the dipole aprotic solvent, as dimethyl formamide.
In dipole aprotic solvent (as dimethyl formamide), the phenol derivatives of general formula IV and the hydride or the ethylate (as sodium hydride, hydrolith or uncle's fourth potassium) of corresponding alkali metal or alkaline-earth metal are reacted, then can in its reaction mixture, obtain the basic metal of general formula IV compound or the salt of alkaline-earth metal.
The generalformula of available currently known methods resulting separation.With known method with resulting generalformula in organic solvent with corresponding inorganic or organic acid (example hydrochloric acid, Hydrogen bromide, sulfuric acid, toxilic acid, fumaric acid, lactic acid) reaction, can make its salt.
The raw material of general formula II and IV is known, the compound that obtains easily.
The compound of general formula III is new, does not introduce in prior art.
Noun " alkyl " refers to the saturated aliphatic hydrocarbon of straight or branched with 1-5 carbon atom, as methyl, ethyl, just-and propyl group, different-propyl group etc.Noun " alkenyl " refers to olefin group such as allyl group, the propenyl etc. of the straight or branched with 2-5 carbon atom.Noun " aralkyl " refers to by aryl substiuted alkyl group, as phenyl, β-styroyl etc.Noun " cycloalkyl " refers to the saturated cyclic aliphatic carbon hydrogen group with 3-8 carbon atom, as cyclobutyl, cyclopentyl, cyclohexyl etc.Noun " halogen " refers to oxygen, chlorine, bromine, iodine atom, preferentially selects chlorine, bromine for use, preferably the chlorine atom.
By R
1And R
2" heterocyclic radical " that generate with adjacent nitrogen-atoms can be 5 yuan of heterocycles or 6 yuan of heterocycles, can contain 1-2 nitrogen-atoms, Sauerstoffatom and/or the sulphur atom that can replace arbitrarily.The heterocyclic group of preferentially selecting for use is pyrrolidyl, piperidyl, morpholinyl, piperazinyl.
The R of preferential former usefulness
1And R
2Be methyl, or generate pyrroles's subbase or piperidino-(1-position only) with adjacent nitrogen-atoms.The R that preferentially selects for use
3Be methyl.
Method of the present invention is suitable for preparing 1-methyl-N especially
5-the 3-[3-(1-piperidyl)-methyl-]-phenoxy group-]-propyl group }-1H-1,2,4-triazole-3,5-diamines and salt thereof.
The major advantage of method of the present invention is as follows:
(a) this method is suitable for the production of commercial size.
(b) do not need special device and equipment.
(c) be easy to obtain in a large number raw material.
(d) owing to removed the isomer of general formula IV compound, and in synthetic required generalformula process, do not need progressively to carry out, two quantity are big to get final product to the intermediate product that equates and only need synthesize, so the overall yield of this synthetic method is far above the overall yield of currently known methods up to now.
Assign embodiment and be described in further detail the present invention, but these embodiment do not limit protection scope of the present invention.
Embodiment 1
N
5-(3-chloropropyl)-1H-1,2,4-triazole-3,5-diamine hydrochloride
5 gram (0.032 mole of N
5-(3-hydroxypropyl)-1H-1,2,4-triazole-3, the 5-diamines is dissolved in 15 milliliters of benzene.Be cooled to 10 ℃, under agitation condition, in this solution, add 4.2 gram (0.035 mole) thionyl chloride.The temperature of reaction mixture is gone up at leisure to room temperature.It is stirred half an hour, filter out the crystallization that has precipitated, wash with benzene.Obtain 6.3 gram required compounds, productive rate 92.8%.It dissolves in air, is the white crystals of the high suction temperature of tool, 130~132 ℃ of fusing points (in sealed tube).
Embodiment 2
N
5-(3-chloropropyl)-1H-1,2,4-triazole-3,5-diamines-hydrochloride
Its preparation process is similar to embodiment 1, and difference only is to add the thionyl chloride of 10.6 milliliters (0.15 moles), and it surpasses and adds part as reaction medium, does not use benzene.Obtain 6.8 gram required compounds, productive rate 94.4%.This product is identical with the compound that embodiment 1 method makes.
Embodiment 3
1-methyl-N
5-(3-chloropropyl)-1H-1,2,4-triazole-diamines-hydrochloride
Prepare title compound with the method similar in appearance to embodiment 2, its difference only is with 8.6 gram (0.05 mole) 1-methyl-N
5-(3-hydroxypropyl)-1H-1,2,4-triazole-3, the 5-diamines is as raw material, and compound of reaction is heated to 60 ℃, stirs 15 minutes.Obtain 10.7 gram required compounds.Productive rate 94.7%, 170~172 ℃ of fusing points (decomposition).
Embodiment 4
1-methyl-N
5-the 3-[3-[(1-piperidyl) methyl]-phenoxy group]-propyl group }-1H-1,2,4-triazole-3,5-diamines
The 3-(1-piperidino methyl that slowly adds 5.7 grams (0.03 mole) in the 1.0 gram oily suspension of (0.033 mole) 80% sodium hydrides at 20 milliliters of anhydrous dimethyl formamides) phenol at room temperature stirs this mixture half an hour.Under room temperature and agitation condition with 3.04 the gram (0.03 mole) triethylamines join in separating bottle 8.1 the gram (0.036 mole) 1-methyl-N
5-(3-chloropropyl)-1H-1,2,4-triazole-3,5-diamines-hydrochloride (in the solution of 15 milliliters of anhydrous dimethyl base acid amides) filters out sedimentary triethylamine hydrochloride, with some anhydrous dimethyl formamide washings.In room temperature and under stirring resulting solution is added in the dimethyl formamide solution of the phenolate that makes with aforesaid method.At room temperature reaction mixture was stirred 72 hours, add 30 ml waters then, use 20 milliliters chloroform extraction three times more at every turn.Merge organic phase, use water extraction three times, each 20 milliliters, with anhydrous magnesium sulfate drying chloroform phase, vacuum boils off chloroform then.Only put gained brown oily residuum (9.6 grams so that its slow crystallization, and then with this example be the mixture of 1: 4 ethyl acetate and hexanaphthene with its recrystallization, obtain 5.6 and restrain required product, productive rate 54.4%, 93~94 ℃ of fusing points.
Embodiment 5
1-methyl-N
5-the 3-[3-[(1-piperidyl)-methyl]-phenoxy group]-propyl group }-1H-1,2,4-triazole-3,5-diamines-fumarate
To be dissolved in the oily crude product that embodiment 4 methods make in 30 milliliters of ethanol, add 3.5 gram (0.03 mole) fumaric acid, and after the reaction mixture dissolving,, place in the refrigerator and spend the night, filter out sedimentary crystallization, use some washing with alcohol its cooling at 50 ℃.Obtain 7.8 gram required compounds, productive rate is 56.4%, 142~145 ℃ of fusing points.
Embodiment 6
1-methyl-N
5-the 3-[3-[(1-piperidyl)-methyl]-phenoxy group]-propyl group }-1H-1,2,4-triazole-3,5-diamines
Except using the 1-methyl-N-(3-chloropropyl of 10.2 grams (0.045 mole))-1H-1,2,4-triazole-3, outside 5-diamines-hydrochloride, other similar process obtains 5.3 gram required compounds, productive rate 51.4% in embodiment 4.Product is identical with the compound of example 4.
Embodiment 7
1-methyl-N
5-the 3-[3-[(1-piperidyl)-methyl]-phenoxy group]-propyl group }-1H-1,2,4-triazole-3,5-diamines
Except 1-methyl-N-(3-chloropropyl with 6.8 grams (0.03 mole))-1H-1,2,4-triazole-3,5-diamines-hydrochloride is outside the raw material, other process homogeneous phase is similar to embodiment 4.Obtain the required product of 4.9 grams.Productive rate 47.6%.Product is identical with the compound of embodiment 4.
Embodiment 8
1-methyl-N
5-3-[3-[1-piperidyl-methylphenoxy]-propyl group]-1H-1,2,4-triazole 3,5-diamines
Be prepared with the method similar in appearance to embodiment 4, difference is to represent sodium hydride with 1.4 gram (0.033 mole) hydroliths.Obtain 5.1 grams institute 4 and need product.Productive rate 49.5%.This product is identical with embodiment 4 prepared compounds.
Embodiment 9
1-methyl-N
5-the 3-[3-[1-pyrrolidyl)-methyl]-phenoxy group]-propyl group]-1H-1,2,4-triazole 3,5-diamines
Except with 5.3 the gram (0.03 mole) 3-(1-pyrrolidyl-methyl)-raw material of phenol as the general formula IV, other preparation process is all with embodiment 4.Obtain 4.9 gram required compounds.Productive rate 49.4%, 94~95 ℃ of fusing points.
Embodiment 10
1-methyl-N
5-the 3-[3-[1-pyrrolidyl)-methyl]-phenoxy group]-propyl group]-1H-1,2,4-triazole 3,5-diamines fumarate
Except the preparation of raw material with the embodiment 9, other process is all identical with embodiment 5.Obtain 7.2 gram required compounds.Productive rate 53.7%, 140~142 ℃ of fusing points.
Embodiment 11
1-methyl-N
5-the 3-[3-[(dimethylamino)-methyl]-phenoxy group]-propyl group }-1H-1,2,4-triazole 3,5-diamines
Except with 4.5 gram (0.03 mole) 3-dimethylaminomethyl-phenol as the raw material, other process is all with embodiment 4, obtains 4.1 gram required compounds.Productive rate 44.9%, fusing point 95-96 ℃.
Embodiment 12
N
5The 3-[-[(-piperidyl)-methyl]-phenoxy group]-propyl group }-1H-1,2,4-triazole-3,5-diamines
Except N-(3-chloropropyl with 7.6 grams (0.036 mole))-1H-1,2,4-triazole-3,5-diamines-hydrochloride is as outside the raw material, and other preparation process is all with embodiment 4.Obtain 4.7 gram required compounds, productive rate 47.9%, 100~101 ℃ of fusing points.
Embodiment 13
N
5-the 3-[3-[(dimethylamino)-methyl]-phenoxy group]-propyl group }-1H-1,2,4-triazole-3,5-diamines
Except restraining (0.036 mole) N with 4.5 gram (0.03 mole) 3-dimethylaminomethyl-phenol and 7.6
5-(3-chloropropyl)-1H-1,2,4-triazole-3,5-diamines-hydrochloride is as outside the raw material, and other preparation process is all with embodiment 4.Obtain 4.2 gram required compounds.Productive rate 48.2%, 91~93 ℃ of fusing points.
Claims (4)
1, shown in a kind of preparation formula I 3,5-diaminostilbene H-1,2, the method for 4-triazole derivative and medicinal acid addition salt thereof,
(R wherein
1And R
2Each represents hydrogen, alkyl, alkenyl, aralkyl or cycloalkyl; Or R
1And R
2Be connected with adjacent nitrogen-atoms and form heterocycle, R
3Represent hydrogen or alkyl),
This method comprises makes the halogenated compound shown in the general formula III
With the basic metal of phenol derivatives shown in the general formula IV or alkaline earth salt (R wherein
1And R
2In the inertia aprotonic solvent, react as defined above),
(Ⅳ)
If desired, resulting generalformula can be converted into its medicinal acid addition salt.
2, in accordance with the method for claim 1, the basic metal or the alkaline earth salt that lead to the formula IV compound comprising preparation in described reaction mixture.
3, according to claim 1 or 2 described methods, comprising adopting dimethyl formamide as solvent.
4, in accordance with the method for claim 1, it is characterized in that with compound shown in general formula III and the general formula IV be raw material, wherein R
1And R
2Be connected with adjacent nitrogen-atoms and generate piperidino-(1-position only) ring, R
3Represent methylidene.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU85315A HU193253B (en) | 1985-01-29 | 1985-01-29 | Process for preparing 3,5-diamino-1,2,4-triazole derivatives |
HU315/85 | 1985-01-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN86100724A CN86100724A (en) | 1986-08-13 |
CN1015456B true CN1015456B (en) | 1992-02-12 |
Family
ID=10949054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN86100724A Expired CN1015456B (en) | 1985-01-29 | 1986-01-29 | Process for preparation of 3,5-diamino-1,2,4-triazole derivatives |
Country Status (18)
Country | Link |
---|---|
JP (1) | JPS61176576A (en) |
CN (1) | CN1015456B (en) |
AR (1) | AR240046A1 (en) |
AT (1) | AT395149B (en) |
CA (1) | CA1285568C (en) |
CS (1) | CS253739B2 (en) |
DD (1) | DD242807A5 (en) |
DE (1) | DE3602648A1 (en) |
DK (1) | DK42986A (en) |
ES (1) | ES8704910A1 (en) |
FI (1) | FI860432A (en) |
GB (1) | GB2170805B (en) |
HU (1) | HU193253B (en) |
IT (1) | IT1190608B (en) |
NO (1) | NO167091C (en) |
PL (1) | PL146491B1 (en) |
PT (1) | PT81935B (en) |
SE (1) | SE8600385L (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2023133B (en) * | 1978-04-26 | 1982-09-08 | Glaxo Group Ltd | Heterocyclic derivatives |
EP0029303B1 (en) * | 1979-10-22 | 1985-01-30 | Glaxo Group Limited | 1,2,4-triazole derivatives, processes for their production and pharmaceutical compositions containing them |
DK558181A (en) * | 1981-01-30 | 1982-07-31 | Smithkline Corp | METHOD OF PREPARING 3,5-DIAMINO-1,2,4-TRIAZOLES |
DE3336410A1 (en) * | 1983-10-06 | 1985-04-18 | Ludwig Heumann & Co GmbH, 8500 Nürnberg | SULFEN AMIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
DE3341750A1 (en) * | 1983-11-18 | 1985-05-30 | Ludwig Heumann & Co GmbH, 8500 Nürnberg | 1,2,4-Triazole derivatives, process for their preparation and medicaments containing these compounds |
-
1985
- 1985-01-29 HU HU85315A patent/HU193253B/en unknown
-
1986
- 1986-01-19 IT IT19218/86A patent/IT1190608B/en active
- 1986-01-27 CS CS86576A patent/CS253739B2/en unknown
- 1986-01-29 SE SE8600385A patent/SE8600385L/en not_active Application Discontinuation
- 1986-01-29 NO NO860324A patent/NO167091C/en unknown
- 1986-01-29 DE DE19863602648 patent/DE3602648A1/en active Granted
- 1986-01-29 FI FI860432A patent/FI860432A/en not_active Application Discontinuation
- 1986-01-29 AR AR302989A patent/AR240046A1/en active
- 1986-01-29 GB GB08602136A patent/GB2170805B/en not_active Expired
- 1986-01-29 AT AT0021086A patent/AT395149B/en not_active IP Right Cessation
- 1986-01-29 DK DK42986A patent/DK42986A/en not_active Application Discontinuation
- 1986-01-29 PT PT81935A patent/PT81935B/en not_active IP Right Cessation
- 1986-01-29 CN CN86100724A patent/CN1015456B/en not_active Expired
- 1986-01-29 ES ES551388A patent/ES8704910A1/en not_active Expired
- 1986-01-29 JP JP61017700A patent/JPS61176576A/en active Granted
- 1986-01-29 CA CA000500565A patent/CA1285568C/en not_active Expired - Lifetime
- 1986-01-29 PL PL1986257689A patent/PL146491B1/en unknown
- 1986-01-29 DD DD86286590A patent/DD242807A5/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AT395149B (en) | 1992-09-25 |
GB2170805A (en) | 1986-08-13 |
IT1190608B (en) | 1988-02-16 |
FI860432A0 (en) | 1986-01-29 |
CA1285568C (en) | 1991-07-02 |
IT8619218A0 (en) | 1986-01-19 |
SE8600385L (en) | 1986-07-30 |
PT81935B (en) | 1987-11-30 |
HU193253B (en) | 1987-08-28 |
SE8600385D0 (en) | 1986-01-29 |
DK42986A (en) | 1986-07-30 |
CN86100724A (en) | 1986-08-13 |
DD242807A5 (en) | 1987-02-11 |
DE3602648C2 (en) | 1990-09-06 |
HUT40632A (en) | 1987-01-28 |
DE3602648A1 (en) | 1986-09-11 |
ATA21086A (en) | 1992-02-15 |
PL257689A1 (en) | 1987-02-09 |
ES8704910A1 (en) | 1987-04-16 |
GB2170805B (en) | 1988-04-27 |
NO860324L (en) | 1986-07-30 |
PL146491B1 (en) | 1989-02-28 |
CS253739B2 (en) | 1987-12-17 |
JPS61176576A (en) | 1986-08-08 |
NO167091C (en) | 1991-10-02 |
NO167091B (en) | 1991-06-24 |
DK42986D0 (en) | 1986-01-29 |
FI860432A (en) | 1986-07-30 |
GB8602136D0 (en) | 1986-03-05 |
PT81935A (en) | 1986-02-01 |
ES551388A0 (en) | 1987-04-16 |
JPH0524906B2 (en) | 1993-04-09 |
AR240046A1 (en) | 1990-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1162409C (en) | Depsipeptide deriv., its intermediate and method for preparing said intermediate | |
CN101041629A (en) | New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it | |
CN1121397C (en) | Method for producing triazolinethione derivatives | |
CN1119645A (en) | Method for producing 1,2-benzisothiazol-3-ones 21678/01 | |
CN1207295C (en) | Method for preparing pyrazo [4,3-d] pyrimidine-7-one and its intermediate | |
CN1077104C (en) | Palladium catalyzed ring closure of triazolyl tryptamine | |
CN1922193A (en) | Chemical process | |
CN86101277A (en) | Trisubstituted phenylformic acid intermediates preparation | |
CN1052979C (en) | Carbazolone derivatives and process for preparing the same | |
CN1558906A (en) | Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof | |
CN1274347A (en) | Method for producing triazolinthion derivatives | |
CN1847218A (en) | Hydroxynaphthalenedicarboxylic acid hydrazide and derivatives thereof as well as process for preparing them | |
CN1033521A (en) | Novel 2-guanidine radicals thiazolium compounds and preparation method thereof, and the intermediate that is used as Famotidine pyridine preparation technology | |
CN1131864C (en) | Chemical synthesis of morpholine derivatives | |
CN1094930C (en) | Quinoxaline and preparation method and application thereof | |
CN1174961C (en) | Intermediate for preparing triazolinone and preparing method thereof | |
CN1015456B (en) | Process for preparation of 3,5-diamino-1,2,4-triazole derivatives | |
CN1558896A (en) | Method and apparatus for preparing hydrazo-dicarbonamide using urea as starting material | |
CN86100228A (en) | The preparation method of polycyclic salts | |
CN1030911A (en) | The method for preparing quinolone carboxylic acid | |
CN1016334B (en) | Process for producing polyarylalkane oligomers containing xylene units | |
CN100345841C (en) | Preparation for the production of 1,2,4-triazolymethyl-oxiranes | |
CN1219752C (en) | Process for preparing substituted hydrazide by using carboxylic acid | |
CN1252052C (en) | Method for stereochemically controlled production of isomerically pure highly substituted azacyclic compounds | |
CN1027260C (en) | Process for preparing acyl cyanides in anhydrous medium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C13 | Decision | ||
GR02 | Examined patent application | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |